tbuckley/cabot-search huggingface dataset:
THE WANING GLORY OF THE LEUCOCYTE.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SPECIAL CONTRIBUTION
Journal: JAMA (1960)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
RHEUMATIC MYOCARDITIS.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
IN GASOLINE WE TRUST
Journal: JAMA (1968)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Izydor Kopernicki
Journal: JAMA (1949)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Chronic Disease and Psychological Invalidism: A Psychosomatic Study
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Lot-release criteria, postlicensure quality control, and the Haemophilus influenzae type b conjugate vaccines
Authors: W. Egan
Journal: JAMA (1995)

In the United States, vaccines are licensed by the Center for Biologics Evaluation and Research (CBER) of the Food and Drug Administration on the basis of their demonstrated safety and efficacy and the demonstrated ability of the manufacturer to produce a consistent product. After licensure, vaccines are generally released to the market on a lot-by-lot basis, following CBER's review of lot-release testing results. A lot is released only if it meets all predefined specifications. A discussion of US vaccine regulation was published recently by Parkman and Hardegree.<sup>1</sup> See also p 849. As reported in this issue ofTHE Journal,<sup>2</sup>during studies of the interchangeability of licensed<i>Haemophilus influenzae</i>type b (Hib) polysaccharide-protein conjugate vaccines, Anderson et al found that a lot of Hib vaccine with the capsular polysaccharide conjugated to the meningococcal outer membrane protein complex (PedvaxHib, Merck and Co, West Point, Pa) produced lower than expected immune
The President Outlines a Program
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Diabetes Report Card for the United States, 1988–1995
Journal: Annals of Internal Medicine (2002)

Summaries for Patients16 April 2002A Diabetes Report Card for the United States, 1988–1995Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-136-8-200204160-00001 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?Diabetes mellitus is a common disease that interferes with the body's ability to store energy from food. The pancreas makes a substance called insulin that helps to store energy from food. Type 1 diabetes mellitus (also called juvenile diabetes) occurs when the pancreas stops making insulin. In type 2 diabetes mellitus (also called adult-onset diabetes), the body makes plenty of insulin but is unable to use it normally. In both cases, the result is high blood sugar levels. Over time, high blood sugar levels can lead to blindness, ... Author, Article, and Disclosure InformationAffiliations: The summary below is from the full report titled “A Diabetes Report Card for the United States: Quality of Care in the 1990s.” It is in the 16 April 2002 issue of Annals of Internal Medicine (volume 136, pages 565-574). The authors are JB Saaddine, MM Engelgau, GL Beckles, EW Gregg, TJ Thompson, and KMV Narayan.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoA Diabetes Report Card for the United States: Quality of Care in the 1990s Jinan B. Saaddine , Michael M. Engelgau , Gloria L. Beckles , Edward W. Gregg , Theodore J. Thompson , and K.M. Venkat Narayan Metrics 16 April 2002Volume 136, Issue 8Page: I-24KeywordsBlood pressureBlood sugarCholesterolHealth care qualityHealth insuranceHealth surveysInsulinPancreasType 1 diabetesType 2 diabetes ePublished: 16 April 2002 Issue Published: 16 April 2002 Copyright & PermissionsCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
BACE1, the Alzheimer’s beta-secretase enzyme, in health and disease
Authors: Robert Vassar
Journal: Molecular Neurodegeneration (2013)

The beta-amyloid (Abeta) peptide is the major constituent of amyloid plaques in Alzheimer's disease (AD) brain and is likely to play a central role in the pathogenesis of this devastating neurodegenerative disorder.The beta-secretase, beta-site amyloid precursor protein cleaving enzyme 1 (BACE1; also called Asp2, memapsin 2), is the enzyme responsible for initiating the generation of Abeta.Thus, BACE1 is a prime drug target for the therapeutic inhibition of Abeta production for the treatment or prevention of AD.Since its discovery over 10 years ago, much has been learned about BACE1.This seminar will describe BACE1 properties, physiological functions, and dysregulation in AD.The therapeutic potential of BACE1 inhibitors for AD will also be considered.Particular focus will be placed upon our novel results demonstrating a role of BACE1 in the axon guidance of olfactory sensory neuron axons to specific odorant receptor glomeruli in the olfactory bulb and the therapeutic implications of these findings.
Erratum
Authors: Alex Anstey, Royal Hospital, Newport Confirmed, Lesley Rhodes, Kevin Mckenna, Hywel Williams, Carron Layfield
Journal: British Journal of Dermatology (2009)

The two day course meets a number of educational objectives, teaching delegates: how to evaluate patients with photosensitivity; how to identify the pros and cons of prephototherapy phototesting in PUVA and UVB; how to identify currently accepted best practice in the practice of phototherapy for it's most common applications and to identify how this differs from practice in their own unit/department.Delegates will acquire the knowledge and skills to evaluate patients with photosensitivity and diagnose the underlying cause; to manage patients with prolonged photosensitivity; and to take on the role of clinical lead for phototherapies in their own unit.
New requirements for authors: signed statements of authorship responsibility and financial disclosure
Authors: G. D. Lundberg
Journal: JAMA (1989)

Editors of peer-reviewed journals have relationships based on trust with authors, readers, owners, editorial board members, reviewers, funding agencies, institutions, students, advertisers, the media, and the public at large. These trust relationships frequently come into conflict, the product of obvious differences in goals, values, and priorities. Other differences arise from faulty communications. Still others arise from ignorance of editorial and authorial ethics and publication laws, sloppiness of work, and sometimes deliberate attempts to deceive. To educate authors and help them avoid the pitfalls of ignorance and to discourage a few from believing that the ethics and laws do not apply to them, peer-reviewed journals codify their policies and procedures in Instructions for Authors.<sup>1</sup>Many journals specify similar instructions such as the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" produced and updated periodically by the International Committee of Medical Journal Editors (the Vancouver Group).<sup>2</sup>In 1985, the Vancouver
Sulfonamide reactions in systemic lupus erythematosus
Authors: P. Cohen
Journal: JAMA (1966)

WITHIN the past five years we have seen four cases of systemic lupus erythematosus (SLE) in which relapse was associated with administration of sulfonamide drugs. Although the warnings relating sulfonamide therapy to apparent initiation or to exacerbation of SLE have been sounded intermittently for three decades,<sup>1-7</sup>we are reporting these cases for two reasons: (1) The textbooks of medicine<sup>2</sup>and a recent monograph on SLE<sup>3</sup>do not emphasize this phenomenon. (2) The proliferation of sulfonamide-related pharmacological agents (for example, acetazoleamide, tolbutamide, chlorothiazide) may, in fact, represent a potential menance for SLE-susceptible persons. The preventive medicine aspects of this problem need reemphasis. The patients were from the medical service of the Peter Bent Brigham Hospital. The lupus erythematosus (LE) cell test and the fluorescent antibody test were done by standard methods. <h3>Report of Cases</h3><h3>Case 1.—</h3> A 39-year-old woman presented with a three-year history of intermittent joint stiffness;
1965 SAMA Medical Art Salon
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Plasma concentration of lipoprotein(a) and the risk of future stroke
Authors: P. M. Ridker
Journal: JAMA (1995)

<h3>Objective.</h3> —To assess prospectively the risk of future stroke associated with baseline concentration of lipoprotein(a), abbreviated Lp(a). <h3>Design.</h3> —Nested case-control study using baseline plasma samples. <h3>Setting.</h3> —Men in the Physicians' Health Study. <h3>Participants.</h3> —A cohort of 14 916 male physicians with no prior history of stroke, transient ischemic attack, or myocardial infarction provided plasma samples at baseline and were followed prospectively for 7.5 years. Samples from 198 physicians who subsequently developed stroke (155 thromboembolic, 35 hemorrhagic, eight indeterminate) were analyzed for Lp(a) concentration together with paired controls, matched for age and smoking habit. <h3>Main Outcome Measure.</h3> —Fatal and nonfatal stroke. <h3>Results.</h3> —Median Lp(a) concentration (8.88 mg/dL [0.23 mmol/L] vs 8.55 mg/dL [0.22 mmol/L]),<i>P</i>=.69) and overall distributions of Lp(a) (<i>P</i>=.54) were similar at baseline in men who did and did not develop future stroke. In analyses controlling for age, smoking status, blood pressure, obesity, and the presence of diabetes, the relative risks (RRs) associated with baseline Lp(a) concentration exceeding the 25th, 50th, 75th, 90th, and 95th percentiles of the control distribution were 1.26, 0.99,1.06, 0.90, and 1.03 (all<i>P</i>values nonsignificant). There was likewise no association in analyses limited to thromboembolic events. For example, among subjects with baseline Lp(a) values exceeding the 95th percentile of the control distribution, the RR of future thromboembolic stroke was 1.01 (<i>P</i>=.9). No evidence of association between Lp(a) and stroke risk was found in analyses limited to individuals with hypercholesterolemia. <h3>Conclusions.</h3> —Among nearly 15000 predominantly white, healthy, middleaged men followed in the Physicians' Health Study for a period of 7.5 years, we found no evidence of association between baseline plasma concentration of Lp(a) and future risk of total or thromboembolic stroke. (<i>JAMA</i>. 1995;273:1269-1273)
Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial.
Authors: Alexander M. Eggermont, Vanna Chiarion-Sileni, Jean Jacques Grob, Reinhard Dummer, Jedd D. Wolchok, Henrik Schmidt, Omid Hamid, Caroline Robert, Paolo Antonio Ascierto, Jon M. Richards, Celeste Lebbe, Virginia Ferraresi, Michael Smylie, Jeffrey S. Weber, Michele Maio, Cyril Konto, Ravichandra Karra Gurunath, Veerle de Pril, Stefan Suciu, Alessandro Testori
Journal: Journal of Clinical Oncology (2014)

LBA9008 Background: Ipilimumab (Ipi), a fully human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen-4 to augment antitumor immune responses, is an approved treatment for advanced melanoma. Here, we report the results of a phase III trial designed to evaluate Ipi as an adjuvant therapy for resected stage III melanoma at high risk of recurrence. Methods: In this randomized, double-blind trial, eligible patients (pts) included those ≥18 yrs of age who underwent complete resection of stage III cutaneous melanoma (excluding lymph node metastasis ≤1 mm or in-transit metastasis). 951 pts were randomized (stratified by stage and region) 1:1 to receive Ipi 10 mg/kg (n=475) or placebo (Pbo, n=476) every 3 wks for 4 doses, then every 3 mos for up to 3 yrs until completion, disease recurrence, or unacceptable toxicity. The primary endpoint was recurrence-free survival (RFS), analyzed on the intent-to-treat population. 512 RFS events (recurrence or death) were needed to provide 90% power to detect an Ipi vs Pbo hazard ratio (HR) of 0.75 (2-sided α=5%). Results: Overall, 20%/44%/36% of pts had stage IIIA/IIIB/IIIC, 42% ulcerated primary, and 58% macroscopic lymph node involvement. At a median follow-up of 2.7 yrs, Ipi significantly improved RFS vs Pbo. RFS benefit was consistent across subgroups (e.g., stage IIIB or IIIC, ulcerated primary). Most common grade 3/4 immune-related adverse events (irAEs) in the Ipi and Pbo arms were gastrointestinal (15.9% vs 0.8%), hepatic (10.6% vs 0.2%), and endocrine (8.5% vs 0%). Most irAEs were managed and resolved using established algorithms. Of 471 pts who started Ipi, 245 (52%) discontinued treatment due to AEs [182 (38.6%) within 12 weeks]; 5 (1.1%) died due to drug-related AEs. Conclusions: In this phase III trial, Ipi as adjuvant therapy provided a clinically and statistically significant improvement in RFS vs Pbo for pts with stage III melanoma at high risk of recurrence. AE profile was generally consistent with that observed in advanced melanoma, although with a higher incidence of endocrinopathies. Clinical trial information: NCT00636168. EudraCT Number: 2007-001974-10. Pbo Ipi No. RFS events 294 234 3-Year rates (SE) 34.8% (2.4%) 46.5% (2.5%) Median (mos) 17.1 26.1 HR (95% CI) 0.75 (0.64–0.90) Log-rank P = 0.0013